|本期目录/Table of Contents|

[1]仇永亮,郭春晓,程文,等.托特罗定缓释片治疗膀胱过度活动症的临床研究[J].医学研究与战创伤救治(原医学研究生学报),2010,12(06):487-489.
　QIU Yong-liang,GUO Chun-xiao,CHENG Wen,et al.Clinical study on treatment of overactive bladder with sustained release tablet tolterodine[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2010,12(06):487-489.
点击复制

托特罗定缓释片治疗膀胱过度活动症的临床研究()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第12卷
期数:
2010年06期
页码:
487-489
栏目:
出版日期:
2010-11-20

文章信息/Info

Title:
Clinical study on treatment of overactive bladder with sustained release tablet tolterodine
文章编号:
1672-271X(2010)06-0487-03
作者:
仇永亮1; 郭春晓1; 程文2; 高建平2; 张征宇2; 葛京平2; 马宏青2; 位志峰2; 徐晓峰2; 徐锋2
1. 210018 江苏南京，南京军区空军司令部门诊部泌尿外科；2. 210002 江苏南京，南京军区南京总医院泌尿外科
Author(s):
QIU Yong-liang1;  GUO Chun-xiao1;  CHENG Wen2; GAO Jian-Ping2; ZHANG Zheng-yu2;  GE Jing-ping2;  MA Hong-qing2;  WEI Zhi-feng2;  XU Xiao-feng2;  XU Feng2.
1.Out-patient Department， the Air Force,Nanjing Military Command, Nanjing, Jiangsu 210018, China; 2.Department of Urology,Nanjing General Hospital of Nanjing Military Command,PLA,Nanjing,Jiangsu 210002, China
关键词:
膀胱过度活动症; 托特罗定缓释片; 托特罗定片; 毒蕈碱受体
Keywords:
overactive bladdeyr;  tolterodine sustaind release tablet;  tolterodine;  oxybutynin
分类号:
R694+.52
DOI:
-
文献标志码:
A
摘要:
目的评价酒石酸托特罗定缓释片治疗膀胱过度活动症的有效性与安全性。方法采用随机、双盲、双模拟平行对照的方法对膀胱过度活动症220例进行托特罗定缓释片剂型组(观察组，110例)和托特罗定原剂型组(对照组，110例)对比研究。托特罗定缓释片，每片4 mg，每日1次，口服；托特罗定片，每片2 mg，每日2次，口服。各连服6周。结果治疗后观察组24 h平均排尿次数由(12.21±3.10)次降至(8.50±2.31)次，24 h平均每次排尿量由(119.80±30.54)ml增至(215.50±68.52)ml、24 h平均尿失禁次数由(2.88±2.5)次减至(0.07±0.38)次。治疗前后比较，有极显著差异(P<0.01)。两组治疗后相比较，无显著性差异。观察组对药物不良反应发生率为38.0%，中毒发生率为18.5%；对照组分别为40.8%和20.0%，总发生率两者无显著性差异(P>0.05)。结论托特罗定缓释片与托特罗定片，其疗效与不良反应基本相同。但托特罗定缓释片，用药次数少，服用方便，为膀胱过度活动症治疗药物的最佳选择。
Abstract:
ObjectiveTo evaluate the efficacy and safety of sustained release tablet tolterodine tartrate in treatment of overactive bladder. Methods220 cases of patients with overactive bladder were divided into A group that treated with tolterodine sustained release tablet and B group that treated with tolterodine with a double-blind, double dummy parallel control method. Tolterodine sustained release tablets was administered in each tablet 4 mg and once daily by oral. Tolterodine tablets was administered in each tablet 2 mg and 2 times per day orally. The treatment was carried out for 6 weeks. ResultsIn A group after treatment, the average voiding frequency decreased from the (12.21 ± 3.10) to (8.50 ± 2.31) times in 24 h. The average 24 h urine volume time increased from (119.80 ± 30.54) to (215.50 ± 68.52) ml. 24 h average number of incontinence episodes reduced from (2.88 ± 2.5) to (0.07 ± 0.38). Before and after treatment, there was significant difference (P<0.01). There was no significant difference between A and B group after treatment. The drug adverse reaction rate in A group was 38.0% and moderate rate was 18.0%. In B group, drug adverse reaction rate and moderate rate were 41.1% and 20.0%. There was no significant difference between the two groups in total incidence. ConclusionTolterodine sustaind release tablets and Tolterodine tablets have similar efficacy and side effects. The tolterodine sustaind release tablet is easy to take and is a best choice for overactive bladder.

参考文献/References:

[1]Chung DE, Te AE. Tolterodine extended-release for overactive bladder[J].Expert Opin Pharmacother,2009,10(13):2181-2194.
[2]Nilvebrantl,Andersson KE,Gillberg PG. Tolterodine a new bladder selective antimuscarinic agent[J].Eur J pharmacol,1997,327(2-3):195-207.
[3]Takei M,Homma Y.Long-term safety,tolerability and efficacy of extended-release tolerodine in the treatment of overactive bladder in Japanese patients[J].Int J Urol,2005,12(2):456-464.
[4]Yarker YE,Guo KL,Fitton A.Oxybutinin:a review of its pharmacodynamic and pharmacokintetic properties,and its therapeutic use in detruson instability[J].Drug Aging,1995,6(3):243-262.
[5]Wein AJ,Rovner ES.The overactive bladder on Overview for primary care hcaleh providers[J].Lnt J Fertil Momen Med,1999,44(1):56-66.
[6]段德宏,杨 勇,吴士良,等.北京地区尿失禁发病率的调查[J].北京医科大学学报,2000,32(1):74-75.
[7]Park SC, Jung SW, Lee JW, et al. The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms [J]. J Endourol,2009,23(11):1913-1917.
[8]Nacrger H,Fry CH.Nilvebrntl effectof tolterodine on electrically induced contractions of isolatedhuman detrusor muscle from stalele and unstable bladders[J].Neurourol Vrodyn,1995,14(3):521-526.
[9]Schiffers M, Sauermann P, Schurch B.The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects[J].World J Urol, 2010, 7(1):36-40.
[10]Chung DE, Te AE, Staskin DR,et al. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams[J].Urology, 2010,75(5):1144-1148.

相似文献/References:

备注/Memo

备注/Memo:
江苏省“六大人才”高峰重点资助项目(2005A2)
更新日期/Last Update: 2010-11-20